Cargando…
Mitosis-targeted anti-cancer therapies: where they stand
The strategy of clinically targeting cancerous cells at their most vulnerable state during mitosis has instigated numerous studies into the mitotic cell death (MCD) pathway. As the hallmark of cancer revolves around cell-cycle deregulation, it is not surprising that antimitotic therapies are effecti...
Autores principales: | Chan, K-S, Koh, C-G, Li, H-Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481136/ https://www.ncbi.nlm.nih.gov/pubmed/23076219 http://dx.doi.org/10.1038/cddis.2012.148 |
Ejemplares similares
-
Cancer: Where We Stand
Publicado: (1951) -
Targeting Apoptosis in AML: Where Do We Stand?
por: Krawiec, Kinga, et al.
Publicado: (2022) -
Photodynamic Therapy for Field Cancerization in the Skin: Where Do We Stand?
por: Bakirtzi, Katerina, et al.
Publicado: (2023) -
Establishment of Fracture Liaison Service in Korea: Where Is It Stand and Where Is It Going?
por: Cha, Yong Han, et al.
Publicado: (2019) -
Cell Therapy for Anal Sphincter Incontinence: Where Do We Stand?
por: Balaphas, Alexandre, et al.
Publicado: (2021)